title: Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.
abstract: The impact of drug resistance mutations induced by nucleoside reverse transcriptase (RT) inhibitors (NRTI) on cytotoxic T-lymphocyte (CTL) recognition of human immunodeficiency virus type 1 strain LAI (HIV-1(LAI)) RT was addressed in 35 treated or untreated patients. Two HIV-1(LAI) RT regions encompassing mutation M41L, L74V, M184V, and T215Y/F were recognized in 75 and 83% mutated and in 33 and 42% unmutated samples, respectively. A total of 41 new CTL epitopes overlapping these mutations were predicted. Mutations enhanced HLA-binding scores of 17 epitopes, decreased scores of 5, and had no effect in 19. Four predicted epitopes containing mutations 41, 74, and 184 were tested and recognized by CD8 cells from mutated or unmutated samples, with frequencies up to 270 gamma interferon spot-forming cells per 10(6) peripheral blood mononuclear cells. Therefore, RT mutations induced by NRTI can increase the immunogenicity of RT for CTL and might allow a better immune control of resistant viruses in vivo, suggesting that specific immune therapy might help prevent these mutations.
authors.affiliation: Laboratoire d'Immunologie Cellulaire et Tissulaire, UMR CNRS 7627, France.
authors.forename: A
authors.initials: A
authors.lastname: Samri
authors.forename: G
authors.initials: G
authors.lastname: Haas
authors.forename: J
authors.initials: J
authors.lastname: Duntze
authors.forename: J M
authors.initials: JM
authors.lastname: Bouley
authors.forename: V
authors.initials: V
authors.lastname: Calvez
authors.forename: C
authors.initials: C
authors.lastname: Katlama
authors.forename: B
authors.initials: B
authors.lastname: Autran
mesh_terms: D019380:Anti-HIV Agents / Q000276:immunology / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D006801:Humans; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018984:Epitopes, T-Lymphocyte; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase